PL1711528T3 - Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 - Google Patents

Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13

Info

Publication number: PL1711528T3
Authority: PL; Poland
Prior art keywords: allergic; treatment; asthma; antibodies; cancer
Prior art date: 2003-12-23

Application number

PL04815598T

Other languages

English (en)

Inventor

Sek Chung Fung

Matthew Moyle

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-23

Filing date

2004-12-23

Publication date

2012-11-30

2004-12-23 Application filed by Genentech Inc filed Critical Genentech Inc

2012-11-30 Publication of PL1711528T3 publication Critical patent/PL1711528T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL04815598T 2003-12-23 2004-12-23 Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 PL1711528T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US53213003P	2003-12-23	2003-12-23
PCT/US2004/043541 WO2005062972A2 (en)	2003-12-23	2004-12-23	Treatment of cancer with novel anti-il 13 monoclonal antibodies
EP04815598A EP1711528B1 (en)	2003-12-23	2004-12-23	Treatment of cancer with novel anti-il 13 monoclonal antibodies

Publications (1)

Publication Number	Publication Date
PL1711528T3 true PL1711528T3 (pl)	2012-11-30

Family

ID=34738751

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL20155148.8T PL3718564T3 (pl)	2003-12-23	2004-12-23	Nowe przeciwciała anty-IL 13 i ich zastosowania
PL04815562T PL1703893T3 (pl)	2003-12-23	2004-12-23	Nowe przeciwciała anty-IL 13 i ich zastosowania
PL14164624T PL2805728T3 (pl)	2003-12-23	2004-12-23	Nowe przeciwciała anty-IL13 i ich zastosowania
PL04815598T PL1711528T3 (pl)	2003-12-23	2004-12-23	Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PL20155148.8T PL3718564T3 (pl)	2003-12-23	2004-12-23	Nowe przeciwciała anty-IL 13 i ich zastosowania
PL04815562T PL1703893T3 (pl)	2003-12-23	2004-12-23	Nowe przeciwciała anty-IL 13 i ich zastosowania
PL14164624T PL2805728T3 (pl)	2003-12-23	2004-12-23	Nowe przeciwciała anty-IL13 i ich zastosowania

Country Status (23)

Country	Link
US (10)	US7674459B2 (pl)
EP (6)	EP2805728B1 (pl)
JP (5)	JP4943161B2 (pl)
KR (5)	KR20150064250A (pl)
CN (4)	CN104013957B (pl)
AT (1)	ATE552850T1 (pl)
AU (1)	AU2004308494B2 (pl)
CA (2)	CA2550651C (pl)
CY (2)	CY1113009T1 (pl)
DK (4)	DK1711528T3 (pl)
ES (5)	ES2967485T3 (pl)
FI (1)	FI3718564T3 (pl)
HR (3)	HRP20120376T1 (pl)
HU (2)	HUE064610T2 (pl)
IL (2)	IL176042A (pl)
LT (2)	LT2805728T (pl)
MX (1)	MX361174B (pl)
PL (4)	PL3718564T3 (pl)
PT (3)	PT1703893E (pl)
RU (3)	RU2487887C2 (pl)
SG (4)	SG10201404273QA (pl)
SI (4)	SI2805728T1 (pl)
WO (2)	WO2005062967A2 (pl)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) *	1999-03-25	2011-02-08	Abbott Gmbh & Co. Kg	Methods for inhibiting the activity of the P40 subunit of human IL-12
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
EP2805728B1 (en) *	2003-12-23	2020-02-05	Genentech, Inc.	Novel anti-IL 13 antibodies and uses thereof
JP2007522246A (ja) *	2004-02-12	2007-08-09	ネクターセラピューティクス	インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法
WO2005080432A2 (en)	2004-02-19	2005-09-01	Genentech, Inc.	Cdr-repaired antibodies
US20090098142A1 (en) *	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) *	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
ATE492563T1 (de)	2004-11-17	2011-01-15	Amgen Inc	Vollständige humane monoklonale antikörper gegen il-13
JP2009510046A (ja) *	2005-09-30	2009-03-12	メドイミューン・リミテッド	インターロイキン−１３抗体組成物
US20070237763A1 (en) *	2005-10-06	2007-10-11	Baylor Research Institute	Compositions and methods for the treatment of cancer
US20070202106A1 (en) *	2005-10-06	2007-08-30	Baylor Research Institute	Compositions and methods for the treatment of cancer
JP5006330B2 (ja)	2005-10-21	2012-08-22	ノバルティスアーゲー	Ｉｌ１３に対するヒト抗体および治療的使用
PL1976877T5 (pl)	2005-11-30	2017-09-29	Abbvie Inc	Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
GB0600488D0 (en) *	2006-01-11	2006-02-22	Glaxo Group Ltd	Immunoglobulins
WO2007085815A2 (en) *	2006-01-24	2007-08-02	Domantis Limited	Ligands that bind il-4 and/or il-13
US10118970B2 (en)	2006-08-30	2018-11-06	Genentech, Inc.	Multispecific antibodies
KR101625961B1 (ko) *	2006-09-08	2016-05-31	애브비 바하마스 리미티드	인터루킨-13 결합 단백질
RU2475265C2 (ru)	2007-01-16	2013-02-20	Эбботт Лэборетриз	Способы лечения псориаза
WO2008131376A2 (en) *	2007-04-23	2008-10-30	Wyeth	Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2008140455A1 (en) *	2007-05-15	2008-11-20	Tanox, Inc.	Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
US8183982B2 (en)	2007-08-14	2012-05-22	Infineon Technologies Ag	System including reply signal that at least partially overlaps request
JP5641599B2 (ja) *	2007-08-24	2014-12-17	学校法人慶應義塾	腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
RU2497545C2 (ru)	2008-03-18	2013-11-10	Эбботт Лэборетриз	Способ лечения псориаза (варианты)
CN112481367A (zh) *	2008-03-31	2021-03-12	健泰科生物技术公司	用于治疗和诊断哮喘的组合物和方法
US8399630B2 (en)	2008-08-20	2013-03-19	Centocor Ortho Biotech Inc.	Engineered anti-IL-13 antibodies, compositions, methods and uses
US8193321B2 (en)	2008-09-03	2012-06-05	Genentech, Inc.	Multispecific antibodies
JP2012509658A (ja) *	2008-11-26	2012-04-26	グラクソグループリミテッド	Ｉｌ−１３に結合するリガンド
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
ES2617777T5 (es)	2010-04-23	2022-10-13	Hoffmann La Roche	Producción de proteínas heteromultiméricas
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
SI3590949T1 (sl)	2010-10-01	2022-09-30	Modernatx, Inc.	Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
CN112168962A (zh) *	2010-12-16	2021-01-05	弗·哈夫曼-拉罗切有限公司	与th2抑制相关的诊断和治疗
DK2663579T3 (en)	2011-01-14	2017-07-31	Univ California	THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
RU2013140685A (ru)	2011-02-04	2015-03-10	Дженентек, Инк.	ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
EP3235508B1 (en)	2011-03-16	2020-12-30	Sanofi	Compositions comprising a dual v region antibody-like protein
JP2014511687A (ja)	2011-03-31	2014-05-19	モデルナセラピューティクスインコーポレイテッド	工学操作された核酸の送達および製剤
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP2763701B1 (en)	2011-10-03	2018-12-19	Moderna Therapeutics, Inc.	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP3091029B1 (en) *	2011-10-31	2022-12-28	F. Hoffmann-La Roche AG	Anti-il13 antibody formulations
KR101483335B1 (ko)	2011-11-01	2015-01-15	울산대학교 산학협력단	골 손실 진단 마커로서의 피브리노겐의 용도
RU2649364C2 (ru)	2011-12-16	2018-04-02	Модерна Терапьютикс, Инк.	Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
CA2864884A1 (en)	2012-03-27	2013-10-03	Genentech, Inc.	Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
EP3520821A1 (en)	2012-04-02	2019-08-07	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9334319B2 (en)	2012-04-20	2016-05-10	Abbvie Inc.	Low acidic species compositions
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
CN104507537A (zh) *	2012-07-13	2015-04-08	宾夕法尼亚大学董事会	用于调节car t细胞的组合物和方法
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
SI2922554T1 (sl)	2012-11-26	2022-06-30	Modernatx, Inc.	Terminalno modificirana RNA
AU2013381687A1 (en)	2013-03-12	2015-09-24	Abbvie Inc.	Human antibodies that bind human TNF-alpha and methods of preparing the same
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
KR20150139905A (ko) *	2013-04-05	2015-12-14	제넨테크, 인크.	항-il-4 항체 및 이중특이적 항체 및 그의 용도
MX2016002799A (es)	2013-09-13	2016-05-26	Genentech Inc	Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
WO2015038888A1 (en)	2013-09-13	2015-03-19	Genentech, Inc.	Methods and compositions comprising purified recombinant polypeptides
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
EP3107574A2 (en) *	2014-02-21	2016-12-28	F. Hoffmann-La Roche AG	Anti-il-13/il-17 bispecific antibodies and uses thereof
US10066267B2 (en)	2014-04-11	2018-09-04	Novartis Ag	Methods of selectively treating asthma using IL-13 antagonists
CA2943707A1 (en)	2014-05-06	2015-11-12	Genentech, Inc.	Production of heteromultimeric proteins using mammalian cells
KR20220119179A (ko) *	2014-06-18	2022-08-26	메디뮨 엘엘씨	N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지
MX384534B (es) *	2014-11-05	2025-03-14	Genentech Inc	Metodos de produccion de proteinas de cadena doble en bacterias.
EP3753948A1 (en)	2014-11-05	2020-12-23	Genentech, Inc.	Methods of producing two chain proteins in bacteria
MX2017006094A (es)	2014-11-10	2017-07-19	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos.
US20160168640A1 (en)	2014-11-10	2016-06-16	Genentech, Inc.	Therapeutic and diagnostic methods for il-33-mediated disorders
HK1247287A1 (zh)	2015-03-16	2018-09-21	F. Hoffmann-La Roche Ag	检测和定量il-13的方法和在诊断和治疗th2相关疾病中的用途
CN115932273A (zh)	2015-04-24	2023-04-07	豪夫迈·罗氏有限公司	鉴定包含结合多肽的细菌的方法
KR102668727B1 (ko)	2015-04-24	2024-05-28	제넨테크, 인크.	다중특이적 항원-결합 단백질
US11390669B2 (en)	2016-04-27	2022-07-19	Abbvie, Inc.	Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
KR102557643B1 (ko) *	2016-09-23	2023-07-20	제넨테크, 인크.	아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
EP3551034A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
EP3580240A1 (en)	2017-02-10	2019-12-18	H. Hoffnabb-La Roche Ag	Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018183932A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
JP7657548B2 (ja) *	2017-04-21	2025-04-07	エランコ・ユーエス・インコーポレイテッド	獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
CN109776677B (zh) *	2017-11-15	2023-11-03	尚华科创投资管理（江苏）有限公司	一种人源化抗il-13抗体及其制备方法和应用
CN113101364B (zh)	2018-05-29	2023-12-01	康诺亚生物医药科技（成都）有限公司	一种自免疫抑制剂的开发和应用
EP3866924A4 (en) *	2018-06-29	2022-07-06	Krystal Biotech, Inc.	COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY
WO2020014650A1 (en) *	2018-07-13	2020-01-16	Memorial Sloan Kettering Cancer Center	Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
WO2020086886A1 (en)	2018-10-25	2020-04-30	Kindred Biosciences, Inc.	Il4/il13 receptor molecule for veterinary use
AU2019383976B2 (en)	2018-11-19	2025-07-03	Bt Bidco, Inc.	Methods and devices for treating a disease with biotherapeutics
CA3129963A1 (en)	2019-03-06	2020-09-10	Regeneron Pharmaceuticals, Inc.	Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
CN113597328B (zh)	2019-03-21	2025-10-31	瑞泽恩制药公司	用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
MX2021013573A (es) *	2019-05-09	2021-12-10	Genentech Inc	Metodos para elaborar anticuerpos.
US12329760B2 (en) *	2019-05-10	2025-06-17	The Trustees Of The University Of Pennsylvania	Methods and compositions for targeting retinoic acid for solid tumor immunotherapy
WO2021076620A1 (en)	2019-10-15	2021-04-22	Eli Lilly And Company	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
US11707610B2 (en)	2019-12-13	2023-07-25	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2021236306A1 (en)	2020-03-13	2022-09-15	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
EP4139344A4 (en) *	2020-04-22	2024-10-16	Elanco US Inc.	Il4/il13 receptor molecules for veterinary use
TWI847170B (zh)	2021-07-16	2024-07-01	美商德米拉股份有限公司	用於治療異位性皮炎之il-13抗體
TWI859566B (zh)	2021-08-13	2024-10-21	美商德米拉股份有限公司	用於治療異位性皮膚炎之il-13抗體
CN118076636A (zh)	2021-09-15	2024-05-24	德米拉公司	Il-13抑制剂用于治疗结节性痒疹
EP4457245A1 (en)	2021-12-30	2024-11-06	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
KR20250007588A (ko) *	2022-04-26	2025-01-14	노파르티스 아게	Il-13 및 il-18을 표적화하는 다중특이적 항체
AU2023293289A1 (en) *	2022-06-17	2024-11-28	Apogee Therapeutics, Inc.	Antibodies that bind interleukin 13 and methods of use
CN118005784A (zh) *	2022-11-08	2024-05-10	上海洛启生物医药技术有限公司	抗il-13长效纳米抗体序列及其应用
CN120826237A (zh)	2023-03-08	2025-10-21	德米拉公司	Il-13抗体用于治疗特应性皮炎
WO2024264003A2 (en) *	2023-06-22	2024-12-26	Paragon Therapeutics, Inc.	Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
WO2025049345A1 (en)	2023-08-25	2025-03-06	Proteologix Us Inc.	Anti-il-13 multispecific antibody constructs and uses thereof
WO2025128984A1 (en)	2023-12-14	2025-06-19	Dermira, Inc.	Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
WO2025128990A1 (en)	2023-12-14	2025-06-19	Dermira, Inc.	Il-13 antibodies for the treatment of perennial allergic rhinitis
WO2025137523A2 (en)	2023-12-20	2025-06-26	Apogee Therapeutics, Inc.	Pharmaceutical formulations of antibodies that bind interleukin 13
TW202535949A (zh)	2023-12-20	2025-09-16	美商必治妥美雅史谷比公司	靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025137410A1 (en)	2023-12-20	2025-06-26	Apogee Therapeutics, Inc.	Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025184453A1 (en)	2024-03-01	2025-09-04	Dermira, Inc.	Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
DE3127674A1 (de)	1981-07-14	1983-02-24	Rheinmetall GmbH, 4000 Düsseldorf	Verfahren und vorrichtung zum belegen einer zielflaeche mit munition
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en)	1985-04-01	1989-01-25	Celltech Ltd	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
WO1989004838A1 (en)	1987-11-25	1989-06-01	Immunex Corporation	Interleukin-1 receptors
WO1989012624A2 (en)	1988-06-14	1989-12-28	Cetus Corporation	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5359037A (en)	1988-09-12	1994-10-25	Yeda Research And Development Co. Ltd.	Antibodies to TNF binding protein I
AU643427B2 (en)	1988-10-31	1993-11-18	Immunex Corporation	Interleukin-4 receptors
JP2919890B2 (ja)	1988-11-11	1999-07-19	メディカルリサーチカウンスル	単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IE63847B1 (en)	1989-05-05	1995-06-14	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US5011778A (en)	1989-05-23	1991-04-30	Otsuka Pharmaceutical Co., Ltd.	Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
NZ236511A (en)	1989-12-20	1993-02-25	Schering Corp	Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1991010741A1 (en)	1990-01-12	1991-07-25	Cell Genesys, Inc.	Generation of xenogeneic antibodies
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de)	1990-03-20	1998-04-16	The Trustees Of Columbia University In The City Of New York, New York, N.Y.	Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
CA2092323A1 (en)	1990-10-01	1992-04-02	George Y. Wu	Targeting viruses and cells for selective internalization by cells
DK0553244T4 (da)	1990-10-05	2005-08-01	Celldex Therapeutics Inc	Målrettet immunostimulering med bispecifikke reagenser
EP0557300B1 (en)	1990-10-29	1997-11-19	Chiron Corporation	Bispecific antibodies, method of production, and uses thereof
DE69133036T2 (de)	1990-11-09	2003-02-06	Stephen D. Gillies	Cytokine immunokonjugate
ES2054601T3 (es)	1991-03-29	1996-04-01	Sanofi Sa	Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados.
WO1992019973A1 (en)	1991-04-26	1992-11-12	Surface Active Limited	Novel antibodies, and methods for their use
DE69231736T2 (de)	1991-05-14	2001-10-25	The Immune Response Corp., Carlsbad	Gerichtete abgabe von genen, die immunogene proteine kodieren
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
DK0587738T3 (da)	1991-06-05	2000-12-18	Univ Connecticut	Destineret levering af gener, som koder for sekretionsproteiner
US5994514A (en)	1991-08-14	1999-11-30	Genentech, Inc.	Immunoglobulin variants
US6329509B1 (en)	1991-08-14	2001-12-11	Genentech, Inc.	Anti-IgE antibodies
US5965709A (en)	1991-08-14	1999-10-12	Genentech, Inc.	IgE antagonists
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
DE69233745D1 (de)	1991-12-02	2008-10-23	Cambridge Antibody Tech	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
AU3434393A (en)	1992-01-17	1993-08-03	Regents Of The University Of Michigan, The	Targeted virus
WO1993015766A1 (en)	1992-02-10	1993-08-19	Seragen, Inc.	Desensitization to specific allergens
EP0627940B1 (en)	1992-03-05	2003-05-07	Board of Regents, The University of Texas System	Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
AU3940293A (en)	1992-04-03	1993-11-08	Alexander T. YOUNG	Gene therapy using targeted viral vectors
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5318564A (en)	1992-05-01	1994-06-07	Hemostatic Surgery Corporation	Bipolar surgical snare and methods of use
DK0598877T3 (da)	1992-06-09	2000-02-21	Hoppe Ag	Falle og dørlås
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5596072A (en)	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
CA2142860A1 (en)	1992-08-21	1994-03-03	Gregorio Aversa	Human interleukin-13
CN1085953A (zh) *	1992-08-21	1994-04-27	先灵公司	人白细胞介素13
CA2141602A1 (en)	1992-08-26	1994-03-03	Philip Leder	Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
KR950703640A (ko)	1992-10-09	1995-09-20	가일 케이,나우톤.	간 보존 세포(liver reserve cells)
EP1024198A3 (en)	1992-12-03	2002-05-29	Genzyme Corporation	Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
EP0604693A1 (en)	1992-12-29	1994-07-06	Schering-Plough	Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6838254B1 (en)	1993-04-29	2005-01-04	Conopco, Inc.	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
ES2120067T3 (es)	1993-09-02	1998-10-16	Dartmouth College	Metodos para inducir tolerancia de celulas t antigeno especifica.
RU2162711C2 (ru) *	1993-09-07	2001-02-10	Смитклайн Бичам Корпорейшн	Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
EP0659766A1 (en)	1993-11-23	1995-06-28	Schering-Plough	Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en)	1994-07-29	1994-09-21	Smithkline Beecham Plc	Novel compounds
IT1270662B (it) *	1994-10-13	1997-05-07	Applied Research Systems	Antagonista della interleuchina-1
US5705154A (en)	1995-03-08	1998-01-06	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
US6037453A (en)	1995-03-15	2000-03-14	Genentech, Inc.	Immunoglobulin variants
US6518061B1 (en)	1995-03-15	2003-02-11	The United States Of America As Represented By The Department Of Health And Human Services	IL-13 receptor specific chimeric proteins and uses thereof
US6165463A (en)	1997-10-16	2000-12-26	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
CA2230758A1 (en)	1995-09-08	1997-03-13	Genzyme Corporation	Improved aav vectors for gene therapy
US6911530B1 (en)	1995-10-23	2005-06-28	Amrad Operations, Pty., Ltd.	Haemopoietin receptor and genetic sequences encoding same
WO1997015663A1 (en)	1995-10-23	1997-05-01	Amrad Operations Pty. Ltd.	A novel haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr)	1995-12-06	1997-06-13	Sanofi Sa	Polypeptide recepteur de l'il-13
CN103275221B (zh)	1996-02-09	2016-08-17	艾伯维生物技术有限公司	结合人TNFα的人抗体
US7078494B1 (en)	1996-03-01	2006-07-18	Genetics Institute, Llc	Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en)	1996-03-01	1998-01-20	Genetics Institute, Inc.	IL-13 cytokine receptor chain
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1997033899A1 (en)	1996-03-14	1997-09-18	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
KR20030096450A (ko)	1996-03-22	2003-12-31	휴먼 게놈 사이언시즈, 인코포레이티드	고사 유도 분자 ⅱ
WO1997047742A1 (en)	1996-06-12	1997-12-18	Smithkline Beecham Corporation	Hr-1 receptor
WO1998010638A1 (en)	1996-09-10	1998-03-19	Amrad Operations Pty. Ltd.	Therapeutic molecules
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
DE69738539T2 (de)	1996-12-03	2009-03-26	Amgen Fremont Inc.	Vollkommen humane Antikörper die EGFR binden
US6743604B1 (en)	1996-12-13	2004-06-01	Smithkline Beecham Corporation	Substances and their uses
GB9625899D0 (en)	1996-12-13	1997-01-29	Glaxo Group Ltd	Substances and their uses
TR200001250T2 (tr)	1997-01-10	2001-03-21	Biogen, Inc	Ati-CD40L bileşikleri ile lupus nefritis tedavisi
PT988056E (pt) *	1997-01-22	2003-09-30	Univ Texas	Metodos e composicoes de factor tecidual para o tratamento da coagulacao e de tumores
ES2172149T3 (es)	1997-04-14	2002-09-16	Micromet Ag	Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6642051B1 (en)	1997-10-21	2003-11-04	Targeted Genetics Corporation	Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
ES2303358T3 (es)	1997-11-03	2008-08-01	Human Genome Sciences, Inc.	Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
US6576232B1 (en)	1998-04-03	2003-06-10	The Penn State Research Foundation	IL13 mutants
US6482403B1 (en)	1998-05-29	2002-11-19	Heska Corporation	Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en)	1998-06-04	2001-10-09	Panacea Pharmaceuticals, Llc	Methods to block IGE binding to cell surface receptors of mast cells
US6222971B1 (en)	1998-07-17	2001-04-24	David Slobodin	Small inlet optical panel and a method of making a small inlet optical panel
GB9820014D0 (en)	1998-09-14	1998-11-04	Cancer Res Campaign Tech	Receptor antagonists and uses thereof
DE19848026A1 (de)	1998-10-17	2000-04-20	Bayer Ag	Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
BR9916209A (pt)	1998-12-14	2001-12-26	Genetics Inst	Cadeia de receptor de citocina
US7553487B2 (en)	1998-12-14	2009-06-30	Genetics Institute, Llc	Method and compositions for treating asthma
CA2361527C (en)	1999-01-26	2004-12-14	California Institute Of Technology	Opto-electronic oscillators having optical resonators
US6468528B1 (en) *	1999-02-01	2002-10-22	Amgen Canada Inc.	Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
EP1222212A4 (en) *	1999-10-06	2005-05-04	Penn State Res Found	MUTANTS OF IL-13
WO2001034645A2 (en)	1999-11-11	2001-05-17	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Mutated il-13 molecules and their uses
US7422376B2 (en)	1999-12-07	2008-09-09	Molex Incorporated	Self-contained fiber optic connector module
DK1270595T3 (da)	2000-03-03	2008-11-10	Kyowa Hakko Kogyo Kk	Anti-CCR4-antistof og dets fragment
CN1323812A (zh)	2000-05-16	2001-11-28	上海博德基因开发有限公司	一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
WO2002055100A2 (en) *	2000-10-20	2002-07-18	Genetics Institute, Llc	Method and composition for inhibition of tumor growth and enhancing an immune response
CA2424371A1 (en)	2000-10-20	2003-04-01	Chugai Seiyaku Kabushiki Kaisha	Agonistic monoclonal antibody fragments
CN100430420C (zh)	2001-08-31	2008-11-05	协和发酵工业株式会社	人cdr-移植抗体及其抗体片段
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1578912A4 (en)	2001-10-26	2007-12-26	Centocor Inc	IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2466492A1 (en)	2001-11-07	2003-05-15	Cytos Biotechnology Ag	Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
CA2469082A1 (en) *	2001-12-04	2003-06-12	Raj K. Puri	Chimeric molecule for the treatment of th2-like cytokine mediated disorders
US20030170724A1 (en) *	2002-03-08	2003-09-11	Anderson David C.	Methods of identifying target polypeptides
WO2003075859A2 (en) *	2002-03-08	2003-09-18	Rigel Pharmaceuticals, Inc.	COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IgE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME
WO2003086451A1 (en) *	2002-04-05	2003-10-23	Centocor, Inc.	Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
WO2004001655A1 (en)	2002-06-14	2003-12-31	The Govermment Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer	Methods of treating and preventing colitis involving il-13 and nk-t cells
US7374894B2 (en) *	2002-07-16	2008-05-20	Rigel Pharmaceuticals, Inc.	Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
JP2006501249A (ja)	2002-08-30	2006-01-12	グラクソ　グループ　リミテッド	ワクチン
US20060147417A1 (en)	2002-08-30	2006-07-06	Claire Ashman	Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
NZ605429A (en) *	2002-09-06	2014-08-29	Amgen Inc	Therapeutic human anti-il-1r1 monoclonal antibody
EP1592777A4 (en)	2003-02-01	2008-06-04	Tanox Inc	METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
ES2257616T3 (es) *	2003-04-25	2006-08-01	Actimis Pharmaceuticals, Inc.	Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
EP2805728B1 (en) *	2003-12-23	2020-02-05	Genentech, Inc.	Novel anti-IL 13 antibodies and uses thereof
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
JP2009510046A (ja)	2005-09-30	2009-03-12	メドイミューン・リミテッド	インターロイキン−１３抗体組成物
JP5006330B2 (ja)	2005-10-21	2012-08-22	ノバルティスアーゲー	Ｉｌ１３に対するヒト抗体および治療的使用
WO2008140455A1 (en)	2007-05-15	2008-11-20	Tanox, Inc.	Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
CN112481367A (zh)	2008-03-31	2021-03-12	健泰科生物技术公司	用于治疗和诊断哮喘的组合物和方法
CN112168962A (zh)	2010-12-16	2021-01-05	弗·哈夫曼-拉罗切有限公司	与th2抑制相关的诊断和治疗

2004
- 2004-12-23 EP EP14164624.0A patent/EP2805728B1/en not_active Expired - Lifetime
- 2004-12-23 SG SG10201404273QA patent/SG10201404273QA/en unknown
- 2004-12-23 PT PT04815562T patent/PT1703893E/pt unknown
- 2004-12-23 EP EP04815598A patent/EP1711528B1/en not_active Expired - Lifetime
- 2004-12-23 PT PT141646240T patent/PT2805728T/pt unknown
- 2004-12-23 CN CN201410077001.6A patent/CN104013957B/zh not_active Expired - Lifetime
- 2004-12-23 KR KR1020157014126A patent/KR20150064250A/ko not_active Ceased
- 2004-12-23 SG SG2012070413A patent/SG184774A1/en unknown
- 2004-12-23 AU AU2004308494A patent/AU2004308494B2/en active Active
- 2004-12-23 DK DK04815598.0T patent/DK1711528T3/da active
- 2004-12-23 CA CA2550651A patent/CA2550651C/en not_active Expired - Lifetime
- 2004-12-23 ES ES20155148T patent/ES2967485T3/es not_active Expired - Lifetime
- 2004-12-23 PL PL20155148.8T patent/PL3718564T3/pl unknown
- 2004-12-23 WO PCT/US2004/043501 patent/WO2005062967A2/en not_active Ceased
- 2004-12-23 ES ES04815598T patent/ES2390344T3/es not_active Expired - Lifetime
- 2004-12-23 MX MX2015002420A patent/MX361174B/es unknown
- 2004-12-23 US US10/583,926 patent/US7674459B2/en active Active
- 2004-12-23 RU RU2006122037/10A patent/RU2487887C2/ru active
- 2004-12-23 PL PL04815562T patent/PL1703893T3/pl unknown
- 2004-12-23 CA CA2551110A patent/CA2551110C/en not_active Expired - Lifetime
- 2004-12-23 LT LTEP14164624.0T patent/LT2805728T/lt unknown
- 2004-12-23 HU HUE20155148A patent/HUE064610T2/hu unknown
- 2004-12-23 CN CN201210299210.6A patent/CN102993302B/zh not_active Expired - Lifetime
- 2004-12-23 DK DK14164624.0T patent/DK2805728T3/da active
- 2004-12-23 ES ES10179775.1T patent/ES2533084T3/es not_active Expired - Lifetime
- 2004-12-23 SI SI200432492T patent/SI2805728T1/sl unknown
- 2004-12-23 EP EP20155148.8A patent/EP3718564B1/en not_active Expired - Lifetime
- 2004-12-23 HU HUE14164624A patent/HUE049161T2/hu unknown
- 2004-12-23 PL PL14164624T patent/PL2805728T3/pl unknown
- 2004-12-23 ES ES14164624T patent/ES2775204T3/es not_active Expired - Lifetime
- 2004-12-23 EP EP10179775.1A patent/EP2332575B1/en not_active Expired - Lifetime
- 2004-12-23 JP JP2006547441A patent/JP4943161B2/ja not_active Expired - Lifetime
- 2004-12-23 SG SG10201900535UA patent/SG10201900535UA/en unknown
- 2004-12-23 AT AT04815562T patent/ATE552850T1/de active
- 2004-12-23 KR KR1020137007978A patent/KR20130041373A/ko not_active Ceased
- 2004-12-23 HR HRP20120376TT patent/HRP20120376T1/hr unknown
- 2004-12-23 DK DK20155148.8T patent/DK3718564T3/da active
- 2004-12-23 SI SI200432525T patent/SI3718564T1/sl unknown
- 2004-12-23 PL PL04815598T patent/PL1711528T3/pl unknown
- 2004-12-23 EP EP10178487A patent/EP2351584A1/en not_active Withdrawn
- 2004-12-23 US US10/583,927 patent/US8067199B2/en not_active Expired - Lifetime
- 2004-12-23 LT LTEP20155148.8T patent/LT3718564T/lt unknown
- 2004-12-23 FI FIEP20155148.8T patent/FI3718564T3/fi active
- 2004-12-23 CN CNA2004800388204A patent/CN1898264A/zh active Pending
- 2004-12-23 SI SI200431888T patent/SI1703893T1/sl unknown
- 2004-12-23 JP JP2006547431A patent/JP4851944B2/ja not_active Expired - Lifetime
- 2004-12-23 EP EP04815562A patent/EP1703893B1/en not_active Expired - Lifetime
- 2004-12-23 KR KR1020067014859A patent/KR101280338B1/ko not_active Expired - Lifetime
- 2004-12-23 CN CN2004800386571A patent/CN1973053B/zh not_active Expired - Lifetime
- 2004-12-23 ES ES04815562T patent/ES2385038T3/es not_active Expired - Lifetime
- 2004-12-23 KR KR1020147003706A patent/KR101627588B1/ko not_active Expired - Lifetime
- 2004-12-23 SI SI200431935T patent/SI1711528T1/sl unknown
- 2004-12-23 SG SG200901976-1A patent/SG151296A1/en unknown
- 2004-12-23 WO PCT/US2004/043541 patent/WO2005062972A2/en not_active Ceased
- 2004-12-23 HR HRP20231569TT patent/HRP20231569T1/hr unknown
- 2004-12-23 PT PT201551488T patent/PT3718564T/pt unknown
- 2004-12-23 DK DK04815562.6T patent/DK1703893T3/da active
- 2004-12-23 KR KR1020127001379A patent/KR20120020203A/ko not_active Ceased
2006
- 2006-05-31 IL IL176042A patent/IL176042A/en active IP Right Grant
2007
- 2007-01-25 JP JP2007015642A patent/JP2007161724A/ja active Pending
2008
- 2008-09-29 US US12/240,604 patent/US8088618B2/en active Active
2010
- 2010-01-14 US US12/687,637 patent/US8318160B2/en not_active Expired - Lifetime
- 2010-10-15 JP JP2010233095A patent/JP2011042669A/ja active Pending
2011
- 2011-05-18 JP JP2011111913A patent/JP2011200242A/ja not_active Withdrawn
- 2011-10-18 US US13/275,658 patent/US8734797B2/en not_active Expired - Lifetime
- 2011-10-18 US US13/275,684 patent/US8734801B2/en not_active Expired - Lifetime
- 2011-11-30 US US13/308,186 patent/US9067994B2/en not_active Expired - Lifetime
2012
- 2012-05-31 CY CY20121100496T patent/CY1113009T1/el unknown
- 2012-06-05 RU RU2012123148/10A patent/RU2012123148A/ru unknown
2013
- 2013-08-20 US US13/971,394 patent/US9605065B2/en active Active
2014
- 2014-04-23 IL IL232210A patent/IL232210A0/en unknown
2017
- 2017-09-29 US US15/721,570 patent/US20180251538A1/en not_active Abandoned
2019
- 2019-11-13 US US16/682,773 patent/US11434287B2/en not_active Expired - Lifetime
2020
- 2020-02-13 RU RU2020106818A patent/RU2752833C1/ru active
- 2020-04-14 HR HRP20200592TT patent/HRP20200592T1/hr unknown
- 2020-04-28 CY CY20201100385T patent/CY1122817T1/el unknown

Also Published As

Publication number	Publication date
DK3718564T3 (da)	2023-11-06
LT3718564T (lt)	2023-12-11
CA2551110C (en)	2016-01-19
KR20140025614A (ko)	2014-03-04
SI1703893T1 (sl)	2012-07-31
JP2007161724A (ja)	2007-06-28
HRP20231569T1 (hr)	2024-03-15
LT2805728T (lt)	2020-05-25
AU2004308494A1 (en)	2005-07-14
US20090214523A1 (en)	2009-08-27
US20120214971A1 (en)	2012-08-23
US7674459B2 (en)	2010-03-09
JP2011200242A (ja)	2011-10-13
AU2004308494B2 (en)	2010-03-18
CN1973053B (zh)	2012-10-10
PL1703893T3 (pl)	2012-09-28
US20180251538A1 (en)	2018-09-06
CN102993302B (zh)	2016-01-20
EP3718564A1 (en)	2020-10-07
RU2752833C1 (ru)	2021-08-09
KR20120020203A (ko)	2012-03-07
US8318160B2 (en)	2012-11-27
EP1711528A4 (en)	2007-07-11
HK1204288A1 (en)	2015-11-13
ES2533084T3 (es)	2015-04-07
CY1122817T1 (el)	2021-05-05
KR101627588B1 (ko)	2016-06-07
CN104013957B (zh)	2016-06-29
PT3718564T (pt)	2023-11-23
PL2805728T3 (pl)	2020-07-13
US20120156203A1 (en)	2012-06-21
US8734801B2 (en)	2014-05-27
KR20150064250A (ko)	2015-06-10
SG10201404273QA (en)	2014-10-30
WO2005062972A2 (en)	2005-07-14
US8734797B2 (en)	2014-05-27
KR20130041373A (ko)	2013-04-24
SG10201900535UA (en)	2019-02-27
SI2805728T1 (sl)	2020-07-31
DK2805728T3 (da)	2020-04-20
KR101280338B1 (ko)	2013-07-09
US20140105897A1 (en)	2014-04-17
JP2007537146A (ja)	2007-12-20
HK1108007A1 (en)	2008-04-25
MX361174B (es)	2018-11-29
CN104013957A (zh)	2014-09-03
US8067199B2 (en)	2011-11-29
RU2012123148A (ru)	2013-12-10
ES2967485T3 (es)	2024-04-30
JP4943161B2 (ja)	2012-05-30
EP2332575B1 (en)	2014-11-12
CN1973053A (zh)	2007-05-30
HRP20120376T1 (hr)	2012-05-31
HK1201457A1 (en)	2015-09-04
HUE049161T2 (hu)	2020-09-28
EP2805728B1 (en)	2020-02-05
US9067994B2 (en)	2015-06-30
US11434287B2 (en)	2022-09-06
FI3718564T3 (fi)	2023-12-15
US20120164144A1 (en)	2012-06-28
IL176042A0 (en)	2006-10-05
US20100266494A1 (en)	2010-10-21
EP3718564B1 (en)	2023-10-11
HRP20200592T1 (hr)	2020-08-07
SI1711528T1 (sl)	2012-10-30
JP4851944B2 (ja)	2012-01-11
IL176042A (en)	2014-04-30
DK1703893T3 (da)	2012-05-07
US8088618B2 (en)	2012-01-03
JP2008500024A (ja)	2008-01-10
ES2390344T3 (es)	2012-11-12
SG184774A1 (en)	2012-10-30
ES2775204T3 (es)	2020-07-24
CA2550651C (en)	2018-01-23
CA2550651A1 (en)	2005-07-14
PT1703893E (pt)	2012-06-01
WO2005062967A2 (en)	2005-07-14
CY1113009T1 (el)	2016-04-13
JP2011042669A (ja)	2011-03-03
US9605065B2 (en)	2017-03-28
PL3718564T3 (pl)	2024-03-18
EP1711528A2 (en)	2006-10-18
EP2332575A1 (en)	2011-06-15
SG151296A1 (en)	2009-04-30
HUE064610T2 (hu)	2024-04-28
US20080008648A1 (en)	2008-01-10
EP1703893B1 (en)	2012-04-11
ES2385038T3 (es)	2012-07-17
RU2006122037A (ru)	2008-01-27
EP2805728A1 (en)	2014-11-26
WO2005062967A3 (en)	2006-12-21
CA2551110A1 (en)	2005-07-14
CN102993302A (zh)	2013-03-27
EP1703893A4 (en)	2008-04-02
PT2805728T (pt)	2020-04-08
ATE552850T1 (de)	2012-04-15
DK1711528T3 (da)	2012-08-20
KR20060130625A (ko)	2006-12-19
IL232210A0 (en)	2014-05-28
US20200291106A1 (en)	2020-09-17
EP1711528B1 (en)	2012-07-18
EP2351584A1 (en)	2011-08-03
SI3718564T1 (sl)	2024-01-31
CN1898264A (zh)	2007-01-17
RU2487887C2 (ru)	2013-07-20
WO2005062972A3 (en)	2005-10-13
EP1703893A2 (en)	2006-09-27
US20110014199A1 (en)	2011-01-20

Publication	Publication Date	Title
PL1711528T3 (pl)	2012-11-30	Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
WO2008134659A3 (en)	2008-12-24	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
TW200503721A (en)	2005-02-01	Aminoquinoline compounds
TW200612985A (en)	2006-05-01	Immunoglobulins
NZ600584A (en)	2014-05-30	Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
MY144906A (en)	2011-11-30	Human antibodies against il13 and therapeutic uses
IL185754A0 (en)	2008-01-06	Novel anti-plgf antibody
WO2004048525A3 (en)	2007-01-18	Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
WO2005056600A3 (en)	2005-10-20	Monoclonal antibodies that bind or neutralize dengue virus
MX2009010765A (es)	2009-10-26	Anticuerpos anti-ige.
WO2005054273A3 (en)	2006-01-26	Humanized antibodies against vascular endothelial growth factor
TW200736274A (en)	2007-10-01	Immunoglobulins
WO2003057006A3 (en)	2003-09-04	Use of antibodies against the muc18 antigen
WO2004031105A3 (en)	2005-04-14	Use of a33 antigens and jam-it
WO2004024098A3 (en)	2004-07-01	Method for the treatment of nephritis using anti-pdgf-dd antibodies
DE60226253D1 (de)	2008-06-05	Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
WO2007084107A3 (en)	2007-10-04	Monoclonal antibodies that neutralize anthrax protective antigen (pa) toxin